The expression levels of c‐FOS appear to determine the sensitivity of MM cells to lenalidomide; c‐FOS mediates lenalidomide resistance via a compensatory increase in the amounts of c‐FOS bound on promoter regions of IKZF1‐target genes after lenalidomide treatment. This evidence concerns the gene FOS and Miyoshi myopathy.